Breast cancer radiation therapy: A bibliometric analysis of the scientific literature

Siegel, 2020, Cancer statistics, 2020, CA Cancer J Clin, 70, 7, 10.3322/caac.21590 Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394, 10.3322/caac.21492 Loibl, 2021, Breast cancer, Lancet, 397, 1750, 10.1016/S0140-6736(20)32381-3 Aristei, 2016, The 2016 Assisi Think Thank Meeting on breast cancer: white paper, Crit Rev Oncol Hematol, 160, 211 Arenas, 2020, The 2018 assisi think thanks meeting: International expert panel white paper, Crit Rev Oncol Hematol, 151, 10.1016/j.critrevonc.2020.102967 Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 2011, Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials, Lancet, 378, 1707, 10.1016/S0140-6736(11)61629-2 EBCTCG (Early Breast Cancer Trialists' Collaborative Group), 2014, Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials, Lancet, 383, 2127, 10.1016/S0140-6736(14)60488-8 Haviland, 2013, The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials, Lancet Oncol, 14, 1086, 10.1016/S1470-2045(13)70386-3 Murray Brunt, 2020, Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects from a multicentre, non-inferiority, randomized, phase 3 trial, Lancet, 395, 1613, 10.1016/S0140-6736(20)30932-6 Coles, 2017, Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomized, controlled, phase 3, non-inferiority trial, Lancet, 390, 1048, 10.1016/S0140-6736(17)31145-5 Bartelink, 2001, European Organization for Research and Treatment of Cancer Radiotherapy and Breast Cancer Groups. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation, N Engl J Med, 345, 1378, 10.1056/NEJMoa010874 Strnad, 2016, Lancet, 387, 229, 10.1016/S0140-6736(15)00471-7 Offersen, 2015, ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, Radiother Oncol, 114, 3, 10.1016/j.radonc.2014.11.030 Meattini, 2022, European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer, Lancet Oncol, 23, e21, 10.1016/S1470-2045(21)00539-8 Franco, 2022, A machine-learning-based bibliometric analysis of the scientific literature on anal cancer, Cancers, 14, 1697, 10.3390/cancers14071697 Aria, 2021, Bibliometrix: An R-tool for comprehensive science mapping analysis, J Informetrics, 11, 959, 10.1016/j.joi.2017.08.007 Fisher, 2002, Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer, N Engl J Med, 347, 1233, 10.1056/NEJMoa022152 Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122 Veronesi, 2002, Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer, N Engl J Med, 347, 1227, 10.1056/NEJMoa020989 Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-47. Goldhirsch, 2013, Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Ann Oncol, 24, 2206, 10.1093/annonc/mdt303 Giuliano, 2011, Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial, JAMA, 305, 569, 10.1001/jama.2011.90 Darby, 2013, Risk of ischemic heart disease in women after radiotherapy for breast cancer, N Engl J Med, 368, 987, 10.1056/NEJMoa1209825 Harris, 2007, American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer, J Clin Oncol, 25, 5287, 10.1200/JCO.2007.14.2364 Rastogi, 2008, Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27, J Clin Oncol, 26, 778, 10.1200/JCO.2007.15.0235 Mansel, 2006, Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial, J Natl Cancer Inst, 98, 599, 10.1093/jnci/djj158 Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717. Coates, 2015, Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015, Ann Oncol, 26, 1533, 10.1093/annonc/mdv221 Goldhirsch, 2009, Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009, Ann Oncol, 20, 1319, 10.1093/annonc/mdp322 Whelan, 2010, Long-term results of hypofractionated radiation therapy for breast cancer, N Engl J Med, 362, 513, 10.1056/NEJMoa0906260 Krag, 2010, Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial, Lancet Oncol, 11, 927, 10.1016/S1470-2045(10)70207-2 Fisher, 2002, Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation, N Engl J Med, 347, 567, 10.1056/NEJMoa020128 van Dongen, 2000, Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial, J Natl Cancer Inst, 92, 1143, 10.1093/jnci/92.14.1143 Buzdar, 2005, Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer, J Clin Oncol, 23, 3676, 10.1200/JCO.2005.07.032 Goldhirsch, 2005, Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005, Ann Oncol, 16, 1569, 10.1093/annonc/mdi326 Gianni, 2010, Lancet, 375, 377, 10.1016/S0140-6736(09)61964-4 Mauri, 2005, Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis, J Natl Cancer Inst, 97, 188, 10.1093/jnci/dji021 Ross, 2009, The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine, Oncologist, 14, 320, 10.1634/theoncologist.2008-0230 Bartelink, 2001, European Organization for Research and Treatment of Cancer Radiotherapy and Breast Cancer Groups. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation, N Engl J Med, 345, 1378, 10.1056/NEJMoa010874 Goldhirsch, 2007, 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007, Ann Oncol, 18, 1133, 10.1093/annonc/mdm271 Ragaz, 2005, Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial, J Natl Cancer Inst, 97, 116, 10.1093/jnci/djh297 Senkus, 2015, ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 26, v8, 10.1093/annonc/mdv298 Fan, 2014, Breast cancer in China, Lancet Oncol, 15, e279, 10.1016/S1470-2045(13)70567-9 Donker, 2014, Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial, Lancet Oncol, 15, 1303, 10.1016/S1470-2045(14)70460-7 DiSipio, 2013, Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis, Lancet Oncol, 14, 500, 10.1016/S1470-2045(13)70076-7 Harbeck, 2017, Breast cancer, Lancet, 389, 1134, 10.1016/S0140-6736(16)31891-8 Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA, Venables K, Bliss JM, Yarnold JR; START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086-1094. Robert, 2011, RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer, J Clin Oncol, 29, 1252, 10.1200/JCO.2010.28.0982 von Minckwitz, 2019, Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer, N Engl J Med, 380, 617, 10.1056/NEJMoa1814017 Hughes, 2013, Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343, J Clin Oncol, 31, 2382, 10.1200/JCO.2012.45.2615 Poortmans, 2015, EORTC Radiation Oncology and Breast Cancer Groups. Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer, N Engl J Med, 373, 317, 10.1056/NEJMoa1415369 Cardoso, 2018, 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†, Ann Oncol, 29, 1634, 10.1093/annonc/mdy192 Vaidya, 2014, TARGIT trialists' group. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial, Lancet, 383, 603, 10.1016/S0140-6736(13)61950-9 Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28(8):1700-1712.